Literature DB >> 31887299

Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.

Li Qiu1, Gan Zhou2, Shan Cao3.   

Abstract

PURPOSE: In acute myeloid leukemia (AML), complete remission can be achieved in parts of patients using cytarabine/anthracycline combination-based chemotherapy, however, drug resistance-related recurrence is still a common cause of treatment failure, leading to high mortality among patients. In our research, we revealed the molecular mechanisms that were sufficient to improve sensitivity of AML cells to the anthracycline daunorubicin (DNR).
METHODS: We evaluated the effects of autophagy and apoptosis induced by DNR using two AML cell lines HL60 and U937.Western blot was preformed to analyze the apoptotic pathway protein expression and flow cytometric analysis was used to detect the level of apoptosis in AML cells. The levels of autophagy-related proteins were detected by western blotting and autophagic vesicles were observed by electron microscopy.
RESULTS: DNR effectively induced autophagy in two AML cell lines HL60 and U937 confirming by upregulation of LC3-II lipidation, formation of autophagosomes. Inhibition of autophagy by pharmacologic inhibitor HCQ promoted apoptosis induced by DNR, suggesting that autophagy played a vital role in pro-survival in AML. Furthermore, ULK1 inhibition by a highly selective kinase inhibitor SBI-0206965 and shRNA enhanced cytotoxicity of DNR against AML cells. Independent of mTOR -ULK1 signaling pathway, activation of autophagy of DNR was proved to be mediated by AMPK (pThr172)/ULK1 pathway.
CONCLUSIONS: These results revealed that pro-survival autophagy induced by ULK1 activation was one of the potential mechanisms of AML resistance to DNR. Targeting ULK1 selectively could be a promising therapeutic strategy to enhance sensitivity of DNR for AML therapy.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Autophagy; Daunorubicin; Drug resistance; ULK1

Mesh:

Substances:

Year:  2019        PMID: 31887299     DOI: 10.1016/j.lfs.2019.117234

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

1.  Stapled Peptide Inhibitors of Autophagy Adapter LC3B.

Authors:  Robert A Cerulli; Livia Shehaj; Hawley Brown; Jennifer Pace; Yang Mei; Joshua A Kritzer
Journal:  Chembiochem       Date:  2020-06-22       Impact factor: 3.164

Review 2.  Autophagy in acute myeloid leukemia: a paradoxical role in chemoresistance.

Authors:  Aafreen Khan; Vivek Kumar Singh; Deepshi Thakral; Ritu Gupta
Journal:  Clin Transl Oncol       Date:  2022-02-26       Impact factor: 3.340

3.  Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.

Authors:  Huiyu Ren; Nicole A Bakas; Mitchell Vamos; Apirat Chaikuad; Allison S Limpert; Carina D Wimer; Sonja N Brun; Lester J Lambert; Lutz Tautz; Maria Celeridad; Douglas J Sheffler; Stefan Knapp; Reuben J Shaw; Nicholas D P Cosford
Journal:  J Med Chem       Date:  2020-11-17       Impact factor: 7.446

4.  Identification of an 11-Autophagy-Related-Gene Signature as Promising Prognostic Biomarker for Bladder Cancer Patients.

Authors:  Chaoting Zhou; Alex Heng Li; Shan Liu; Hong Sun
Journal:  Biology (Basel)       Date:  2021-04-27

Review 5.  A Review of ULK1-Mediated Autophagy in Drug Resistance of Cancer.

Authors:  Li Liu; Lu Yan; Ning Liao; Wan-Qin Wu; Jun-Ling Shi
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

Review 6.  The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?

Authors:  Jing-Li Xu; Li Yuan; Yan-Cheng Tang; Zhi-Yuan Xu; Han-Dong Xu; Xiang-Dong Cheng; Jiang-Jiang Qin
Journal:  Front Cell Dev Biol       Date:  2020-12-03

Review 7.  Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies.

Authors:  Malina Xiao; Alice Benoit; Meriem Hasmim; Caroline Duhem; Guillaume Vogin; Guy Berchem; Muhammad Zaeem Noman; Bassam Janji
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

Review 8.  The role of autophagy in targeted therapy for acute myeloid leukemia.

Authors:  Wenxin Du; Aixiao Xu; Yunpeng Huang; Ji Cao; Hong Zhu; Bo Yang; Xuejing Shao; Qiaojun He; Meidan Ying
Journal:  Autophagy       Date:  2020-09-22       Impact factor: 16.016

9.  Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer.

Authors:  Michael C J Quinn; Karen McCue; Stuart MacGregor; Georgia Chenevix-Trench; Wei Shi; Sharon E Johnatty; Jonathan Beesley; Andrew Civitarese; Tracy A O'Mara; Dylan M Glubb; Jonathan P Tyrer; Sebastian M Armasu; Jue-Sheng Ong; Puya Gharahkhani; Yi Lu; Bo Gao; Ann-Marie Patch; Peter A Fasching; Matthias W Beckmann; Diether Lambrechts; Ignace Vergote; Digna R Velez Edwards; Alicia Beeghly-Fadiel; Javier Benitez; Maria J Garcia; Marc T Goodman; Thilo Dörk; Matthias Dürst; Francesmary Modugno; Kirsten Moysich; Andreas du Bois; Jacobus Pfisterer; Klaus Bauman; Beth Y Karlan; Jenny Lester; Julie M Cunningham; Melissa C Larson; Bryan M McCauley; Susanne K Kjaer; Allan Jensen; Claus K Hogdall; Estrid Hogdall; Joellen M Schildkraut; Marjorie J Riggan; Andrew Berchuck; Daniel W Cramer; Kathryn L Terry; Line Bjorge; Penelope M Webb; Michael Friedlander; Tanja Pejovic; Melissa Moffitt; Rosalind Glasspool; Taymaa May; Gabrielle E V Ene; David G Huntsman; Michelle Woo; Michael E Carney; Samantha Hinsley; Florian Heitz; Sian Fereday; Catherine J Kennedy; Stacey L Edwards; Stacey J Winham; Anna deFazio; Paul D P Pharoah; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-06-23       Impact factor: 4.090

Review 10.  Chemotherapy: a double-edged sword in cancer treatment.

Authors:  Nafiseh Behranvand; Farzad Nasri; Reza Zolfaghari Emameh; Pouria Khani; Asieh Hosseini; Johan Garssen; Reza Falak
Journal:  Cancer Immunol Immunother       Date:  2021-08-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.